Neumora Therapeutics IPO
Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases including depression and other neurological disorders. The company's precision medicine approach to neuroscience and its clinical pipeline have attracted investor interest in the challenging but high-potential brain therapeutics market.
Key Facts
| Industry | Biotechnology |
| Founded | 2021 |
| Headquarters | Watertown, MA |
| Employees | ~200 |
| Website | neumora.com |
| Funding | Public company since February 2023. Raised ~$420M in private funding before IPO |
About Neumora Therapeutics
Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing precision medicines for brain diseases by leveraging computational approaches and biomarker-driven drug development. The company was formed through the combination of multiple neuroscience programs and represents one of the largest-ever venture investments in neuroscience drug development, with a focus on conditions including depression, Alzheimer's disease, and other neurological disorders.
The company's approach combines large-scale data analysis, advanced computational methods, and biomarker identification to develop targeted therapies that address the underlying biology of brain diseases rather than just treating symptoms. Neumora went public in February 2023 and is advancing multiple clinical programs, representing a new generation of neuroscience companies that apply modern data science and precision medicine approaches to historically challenging therapeutic areas.
IPO Status
Neumora Therapeutics went public in February 2023 through a traditional IPO, raising approximately $250 million. The company trades on NASDAQ under the ticker symbol 'NMRA', pricing shares at $17 each for its public debut. The IPO came during a challenging period for biotech public offerings, but Neumora's focus on precision neuroscience and its clinical-stage pipeline helped attract institutional investors. Since going public, the company has continued advancing its clinical programs while navigating the typical volatility associated with clinical-stage biotech stocks.
Competitors
Frequently Asked Questions
Does Neumora Therapeutics have a stock?
Yes, Neumora Therapeutics completed its IPO in February 2023, raising approximately $250 million. The neuroscience-focused biotech company trades on NASDAQ under ticker 'NMRA'.
When is the Neumora Therapeutics IPO date?
Neumora Therapeutics already went public in February 2023, so there is no upcoming IPO. The company completed its initial public offering and began trading on NASDAQ.
How can I buy Neumora Therapeutics stock?
You can buy Neumora Therapeutics stock through any brokerage platform as it trades on NASDAQ under ticker 'NMRA'. Shares are available for purchase during regular trading hours through standard investment accounts.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts